ABIONYX Pharma: Monthly statement of total voting rights and shares forming the company’s share capital
06 Janvier 2021 - 7:23PM
Business Wire
Article L233-8-II of the French Commercial
Code
Article 223-16 of the General Regulations of
the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX):
Market: Euronext Paris, Compartment C ISIN code:
FR0012616852
Date
Number of shares outstanding
Total voting rights
Total gross (1)
Total net (2)
December 31, 2020
24 642 664
24 642 664
24 396 085
- The total number of gross (or “theoretical”) voting rights is
used as the basis for calculating threshold crossings. In
accordance with Article 223-11 of the AMF General Regulations, this
number is calculated on the basis of all shares to which voting
rights are attached, including those for which voting rights have
been suspended.
- The total number of net (or “exercisable at a Shareholders’
Meeting”) voting rights is calculated without taking into account
shares for which voting rights have been suspended. It is released
in order to ensure that the public is properly informed, in
accordance with the recommendation made by the AMF on 17 July
2007.
About ABIONYX Pharma
ABIONYX Pharma is a new generation biotech company dedicated to
the discovery and development of innovative therapies for patients.
The biotech assets inherited from CERENIS Therapeutics constitute a
rich portfolio of valuable programs for the treatment of metabolic
diseases as well as with a HDL targeted drug delivery platform.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210106005759/en/
NewCap Investor relations Louis-Victor Delouvrier
abionyx@newcap.eu +33 (0)1 44 71 98 53
NewCap Media relations Nicolas Merigeau abionyx@newcap.eu
+33 (0)1 44 71 94 98
Abionyx Pharma (EU:ABNX)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Abionyx Pharma (EU:ABNX)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024
